| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8731963 | JAZZ | Sensitive drug distribution system and method |
Dec, 2022
(9 months ago) | |
|
US8731963 (Pediatric) | JAZZ | Sensitive drug distribution system and method |
Jun, 2023
(3 months ago) | |
| US9132107 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(9 years from now) | |
| US8591922 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(9 years from now) | |
| US11554102 | JAZZ | NA |
Jan, 2033
(9 years from now) | |
| US10195168 | JAZZ | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders |
Jan, 2033
(9 years from now) | |
| US8901173 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(9 years from now) | |
| US10675258 | JAZZ | Method of using gamma-hydroxybutyrate compositions for the treatment of disorders |
Jan, 2033
(9 years from now) | |
| US9050302 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(9 years from now) | |
| US8772306 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(9 years from now) | |
| US10213400 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(9 years from now) | |
| US9486426 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(9 years from now) | |
| US10864181 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(9 years from now) | |
| US11253494 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(9 years from now) | |
|
US10213400 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US11253494 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US8772306 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US9050302 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US9486426 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10864181 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
| US11426373 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Sep, 2037
(13 years from now) | |
Xywav is owned by Jazz.
Xywav contains Calcium Oxybate; Magnesium Oxybate; Potassium Oxybate; Sodium Oxybate.
Xywav has a total of 21 drug patents out of which 2 drug patents have expired.
Expired drug patents of Xywav are:
- US8731963
- US8731963*PED
Xywav was authorised for market use on 21 July, 2020.
Xywav is available in solution;oral dosage forms.
Xywav can be used as method of reducing adverse effects in patients suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium, method of treating a patient with a prescription drug using a computer database in a computer system for distribution, method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered., method of reducing adverse effects in patients who are concomitantly administered a salt of gamma-hydroxybutyrate and divalproex sodium; method of treating patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered, treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb administered between 2 and 4 hours after eating, method of treating patients with idiopathic hypersomnia with sodium oxybate when divalproex sodium is concomitantly administered; method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered., treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb, method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered.
The generics of Xywav are possible to be released after 19 September, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 12, 2028 |
| New Product (NP) | Jul 21, 2023 |
| New Indication (I) | Aug 12, 2024 |
Market Authorisation Date: 21 July, 2020
Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution; Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years ...
Dosage: SOLUTION;ORAL
XYWAV family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic